Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Licenses DNA-Methylation IP From Veridex for a Prostate Cancer Dx

NEW YORK (GenomeWeb News) — LabCorp today said it has licensed DNA-methylation technology from Veridex that may help it develop and market an assay to detect prostate cancer.
 
The reference lab giant said its assay will quantify in human samples the level of the gene GST-Pi, which has been linked to prostate cancer.
 
If the technology is used in conjunction with histopathology testing it may “provide a more sensitive and accurate detection of prostate cancer than histology alone,” LabCorp said.
 
The company said it will offer the assay for use on biopsies presenting “suspicious histopathology,” and for patients showing repeatedly elevated prostate specific antigen values but who have repeatedly negative biopsies.
 
LabCorp said it is the first full-service, national laboratory to license this IP in the US.
 
Financial terms of the agreement were not released.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.